Drug Information

Drug General Information
Drug ID
D03RRJ
Former ID
DNC000803
Drug Name
Iodine-131-tositumomab
Drug Type
Antibody
Indication Discovery agent Phase 2 [523216]
Formula
C44H39ClN8O5
PubChem Compound ID
9918746
Target and Pathway
Target(s) B-lymphocyte antigen CD20 Target Info [535062], [536721]
KEGG Pathway Hematopoietic cell lineage
References
Ref 523216ClinicalTrials.gov (NCT01224821) Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies. U.S. National Institutes of Health.
Ref 535062A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000 Nov 1;96(9):2934-42.
Ref 536721Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5. Epub 2008 May 23.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.